Description

The CJC-1295 (with DAC) + Ipamorelin Combination Bundle is designed to replicate both the long-acting and pulsatile components of the body’s natural growth hormone (GH) system.

CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone–releasing hormone (GHRH) analog engineered to remain active in circulation for extended periods. This allows for sustained stimulation of GH and IGF-1 levels, supporting research into body composition, recovery, metabolic activity, and anti-aging pathways.

Ipamorelin is a selective growth hormone secretagogue that triggers short, physiologic GH pulses by stimulating ghrelin receptors without significantly affecting cortisol or prolactin. It is widely studied for its ability to support lean mass, recovery, and sleep-associated GH release.

When used together, CJC-1295 with DAC and Ipamorelin create a synergistic growth hormone research protocol that combines:

• Long-duration GH elevation

• Natural pulsatile GH release

• Improved recovery signaling

• Enhanced metabolic and regenerative pathways

This dual-mechanism approach closely mimics the way the endocrine system regulates growth hormone naturally.

---

Why These Peptides Are Supplied in Separate Vials

Although CJC-1295 with DAC and Ipamorelin are commonly used together in research protocols, they are never mixed in the same vial.

Each peptide has different molecular stability, pH tolerance, and degradation kinetics. When combined in solution, peptides can:

• Break down more rapidly

• Lose biological activity

• Form unstable peptide interactions

• Reduce overall potency and shelf life

To ensure maximum purity, accurate dosing, and pharmaceutical-grade stability, NordisPharma provides CJC-1295 (with DAC) and Ipamorelin in separate sterile vials. This preserves:

• Long-term peptide integrity

• Precise concentration

• Consistent research reliability

They are intended to be used together as a coordinated protocol, but stored separately for optimal performance and stability.

The CJC-1295 (with DAC) + Ipamorelin Combination Bundle is designed to replicate both the long-acting and pulsatile components of the body’s natural growth hormone (GH) system.

CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone–releasing hormone (GHRH) analog engineered to remain active in circulation for extended periods. This allows for sustained stimulation of GH and IGF-1 levels, supporting research into body composition, recovery, metabolic activity, and anti-aging pathways.

Ipamorelin is a selective growth hormone secretagogue that triggers short, physiologic GH pulses by stimulating ghrelin receptors without significantly affecting cortisol or prolactin. It is widely studied for its ability to support lean mass, recovery, and sleep-associated GH release.

When used together, CJC-1295 with DAC and Ipamorelin create a synergistic growth hormone research protocol that combines:

• Long-duration GH elevation

• Natural pulsatile GH release

• Improved recovery signaling

• Enhanced metabolic and regenerative pathways

This dual-mechanism approach closely mimics the way the endocrine system regulates growth hormone naturally.

---

Why These Peptides Are Supplied in Separate Vials

Although CJC-1295 with DAC and Ipamorelin are commonly used together in research protocols, they are never mixed in the same vial.

Each peptide has different molecular stability, pH tolerance, and degradation kinetics. When combined in solution, peptides can:

• Break down more rapidly

• Lose biological activity

• Form unstable peptide interactions

• Reduce overall potency and shelf life

To ensure maximum purity, accurate dosing, and pharmaceutical-grade stability, NordisPharma provides CJC-1295 (with DAC) and Ipamorelin in separate sterile vials. This preserves:

• Long-term peptide integrity

• Precise concentration

• Consistent research reliability

They are intended to be used together as a coordinated protocol, but stored separately for optimal performance and stability.